Picture loading failed.

Pre-Made Vopratelimab biosimilar, Whole mAb, Anti-ICOS Antibody: Anti-AILIM/CD278/CVID1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

An agonistic humanized monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential antineoplastic activity. Upon administration, vopratelimab targets and binds to ICOS expressed on certain T cells.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-629-1mg 1mg 3090
GMP-Bios-ab-629-10mg 10mg Inquiry
GMP-Bios-ab-629-100mg 100mg Inquiry
GMP-Bios-ab-629-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Vopratelimab biosimilar, Whole mAb, Anti-ICOS Antibody: Anti-AILIM/CD278/CVID1 therapeutic antibody
INN Name Vopratelimab
TargetICOS
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2017
Year Recommended2018
CompaniesJounce Therapeutics
Conditions Approvedna
Conditions ActiveSolid tumours;Urogenital cancer;Non-small cell lung cancer
Conditions Discontinuedna
Development Techna